ZBH Stock Forecast & Price Target

Zimmer Biomet Holdings has demonstrated strong performance in the orthopedic reconstructive market, with a reported global market share increase of 20 basis points to 32.9%, alongside notable gains in both knee and hip segments. Specifically, knee sales reached $911 million, surpassing consensus estimates and growing by 6.9%, while hip sales also exceeded expectations at $555 million with a 4.9% growth rate. The company's strategic focus on technology and robotics is reflected in a 6.6% growth in related sectors, suggesting an optimistic trajectory for overall revenue growth despite an increase in SG&A expenses.

Zimmer Biomet Holdings is facing a negative outlook due to lowered revenue growth estimates across various segments, projecting reported growth of only 5.4% year-over-year for FY26, with organic growth expectations as low as 3.1%. The company's operating margin has declined by 170 basis points year-over-year, indicating that gross margin improvements have been overshadowed by rising selling, general, and administrative expenses. Additionally, challenges such as slower sales of the ROSA robot, disappointing new product performances, and heightened competitive pressures contribute to a forecast of potential revenue growth slowing to 2% or less, warranting a valuation discount compared to peers.